Form4insider filings, from the source

SEC Form 4 · accession 0001741533-26-000010

Kiniksa Pharmaceuticals International, plc · KNSA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John F. Paolini
Officer — CHIEF MEDICAL OFFICER
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:43 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001730430

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Class A Ordinary ShareF1Sep 1, 2026M2,497—A68,120D
Class A Ordinary ShareF1Sep 1, 2026M1,624—A69,744D
Class A Ordinary ShareF1Sep 1, 2026M1,750—A71,494D
Class A Ordinary ShareF1Sep 1, 2026M2,457—A73,951D
Class A Ordinary ShareSep 1, 2026F4,029$79.28D69,922D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Share UnitF1,F2—Sep 1, 2026A6,700A——Class A Ordinary Share6,7006,700D
Share OptionF3$79.28Sep 1, 2026A26,750A—Aug 31, 2036Class A Ordinary Share26,75026,750D
Restricted Share UnitF1,F4—Sep 1, 2026M2,457D——Class A Ordinary Share2,4577,371D
Restricted Share UnitF1,F5,F2—Sep 1, 2026M1,750D——Class A Ordinary Share1,7503,500D
Restricted Share UnitF1,F6—Sep 1, 2026M1,624D——Class A Ordinary Share1,6241,624D
Restricted Share UnitF1,F7—Sep 1, 2026M2,497D——Class A Ordinary Share2,4970D

Explanation of responses